Patents by Inventor Adam Golos

Adam Golos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127374
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127373
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127375
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10174027
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10174028
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10138243
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: November 27, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10023570
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 17, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20180186790
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 5, 2018
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20180186791
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 3, 2018
    Publication date: July 5, 2018
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20180179203
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 3, 2018
    Publication date: June 28, 2018
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20170096425
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: July 15, 2016
    Publication date: April 6, 2017
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski